TOM1L2: A Potential Drug Target and Biomarker (G146691)

Target Name: TOM1L2

NCBI ID: G146691

TOM1L2

TOM1L2: A Potential Drug Target and Biomarker

TOM1L2, also known as myb1-like 2, is a protein that is expressed in various tissues throughout the body. It is a key regulator of cell growth and differentiation, and is known to play a role in the development and progression of many diseases. In this article, we will discuss the potential implications of TOM1L2 as a drug target and biomarker.

The discovery and characterization of TOM1L2

TOM1L2 was first identified as a gene encoding a protein with 196 amino acid residues using transcriptomic assays. The protein is expressed in a variety of tissues, including muscle, pancreas, and brain, and is highly conserved across different species.

The function of TOM1L2 is not well understood, but its role in cell growth and differentiation is known to be critical. TOM1L2 has been shown to play a role in the regulation of cell proliferation, cell differentiation, and cell-cell adhesion. It has also been shown to play a role in the development and progression of many diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

As a drug target, TOM1L2 may be used to treat a variety of diseases

The potential drug targets for TOM1L2 are vast, and its role in various diseases makes it an attractive target for drug development. One of the main targets for TOM1L2 is the regulation of cell proliferation. TOM1L2 has been shown to play a role in the regulation of cell cycle progression, and it has been shown to inhibit the activity of the oncogene transforming growth factor-尾1 (TGF-β1). This may make it an effective target for drugs that are currently used to treat cancers, such as inhibitors of TGF-β1.

Another potential target for TOM1L2 is the regulation of cell differentiation. TOM1L2 has been shown to play a role in the regulation of cell-cell adhesion, and it has been shown to promote the transformation of stem cells into functional tissues. This may make it an effective target for drugs that are currently used to treat neurodegenerative diseases, such as neuroprotective agents.

In addition to its potential as a drug target, TOM1L2 may also be used as a biomarker. The regulation of cell growth and differentiation by TOM1L2 may be affected by various factors, including genetic and environmental factors. By studying the expression and function of TOM1L2, researchers may be able to gain insights into the underlying mechanisms of many diseases. This may make TOM1L2 an effective biomarker for a variety of diseases.

Conclusion

In conclusion, TOM1L2 is a protein that has been shown to play a critical role in the regulation of cell growth and differentiation. Its potential as a drug target and biomarker make it an attractive target for further research and development. Further studies are needed to fully understand the function and potential of TOM1L2, and to develop safe and effective drugs that can treat its associated diseases.

Protein Name: Target Of Myb1 Like 2 Membrane Trafficking Protein

Functions: Acts as a MYO6/Myosin VI adapter protein that targets myosin VI to endocytic structures (PubMed:23023224). May also play a role in recruiting clathrin to endosomes (PubMed:16412388). May regulate growth factor-induced mitogenic signaling (PubMed:16479011)

The "TOM1L2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TOM1L2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets